J. Oeh

发表

Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.

D. Sampath, P. Dragovich, T. O'Brien, 2015, Toxicological sciences : an official journal of the Society of Toxicology.

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Bioorganic & medicinal chemistry letters.

Prediction of drug distribution in subcutaneous xenografts of human tumor cell lines and healthy tissues in mouse: application of the tissue composition-based model to antineoplastic drugs.

B. Liederer, S. Gould, C. Hop, 2015, Journal of pharmaceutical sciences.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

C. Ly, S. Sideris, S. Malek, 2012, Journal of medicinal chemistry.

Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors

Scott E. Martin, F. Gnad, Zhaoshi Jiang, 2022, Nature Communications.

Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway

Zhaoshi Jiang, I. Kasman, Z. Modrušan, 2012, The EMBO journal.

Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by 19F–MRI and Multispectral Analysis

M. Hedehus, F. Peale, R. Carano, 2017, Neoplasia.

Cancer Therapy: Preclinical TargetingActivatedAktwithGDC-0068, aNovel SelectiveAkt Inhibitor That Is Efficacious in Multiple Tumor Models

Tyler T. Risom, M. Belvin, S. Gross, 2013 .

Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.

Jun Liang, J. Blake, B. Brandhuber, 2012, Journal of medicinal chemistry.

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo.

P. Sabbatini, J. Eksterowicz, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.

Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.

N. van Bruggen, M. Hedehus, F. Peale, 2013, Neoplasia.

Mapping In Vivo Tumor Oxygenation within Viable

M. Hedehus, F. Peale, N. Bruggen, 2013 .

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Leslie B. Lee, D. Sampath, P. Jackson, 2013, Neoplasia.

Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor

D. Sampath, P. Dragovich, B. Liederer, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery and structure-activity relationship of 2-phenyl-oxazole-4-carboxamide derivatives as potent apoptosis inducers.

L. Qiu, A. Estevez, P. Sabbatini, 2006, Bioorganic & medicinal chemistry letters.

Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.

N. van Bruggen, H. Koeppen, L. Friedman, 2013, Neoplasia.

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Tyler T. Risom, M. Belvin, S. Gross, 2013, Clinical Cancer Research.

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Mamie Yu, A. Daemen, R. Houtman, 2019, Cell.

VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models12

M. Hedehus, R. Carano, D. Sampath, 2019, Neoplasia.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

M. Amiot, F. Peale, Leslie B. Lee, 2016, Molecular Cancer Therapeutics.

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

W. Forrest, Kyung Song, L. Friedman, 2021, bioRxiv.

Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models

F. Peale, Leslie B. Lee, W. Fairbrother, 2012 .

Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity

S. Rutz, Z. Modrušan, James Ziai, 2022, Nature Immunology.

Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.

Leslie B. Lee, D. Sampath, P. Jackson, 2013, Neoplasia.

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

Siew K. Yeap, N. C. Ray, Jun Liang, 2021, Journal of medicinal chemistry.

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

M. Belvin, L. Molinero, D. Sampath, 2018, Blood.

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Dhara N. Amin, N. Johnson, M. Krem, 2023, American journal of hematology.

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.

N. Skelton, D. Sampath, K. Bair, 2016, Journal of medicinal chemistry.

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Yang Xiao, Lei Zhang, Deepak Sampath, 2013, Bioorganic & medicinal chemistry letters.

Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker.

R. Rowntree, B. Vollmar, I. Wertz, 2018, Chemistry.

Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes

A. Daemen, J. Giltnane, L. Friedman, 2019, Poster Session Abstracts.